Nicotinamide Riboside vs NMN: How These Two NAD+ Precursors Actually Compare

Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are the two NAD+ precursors that have been carried furthest into human trials. Both are forms of vitamin B3 that cells can turn into NAD+, and both have been shown to raise NAD+-related markers in blood. The practical differences come down to where each sits in the pathway and what each has been tested for.

This article is for general education and is not medical advice. Talk to your doctor before starting a supplement, especially if you take prescription medication.

Where they sit in the pathway

In the salvage pathway cells use to recycle NAD+, NR is first converted into NMN, and NMN is then converted into NAD+. NMN is therefore one step closer to the finished molecule. That is a biochemical difference; on its own it does not prove that one works better in people.

NR in human trials

• Raises NAD+ in a dose-dependent way: in an eight-week randomised, placebo-controlled trial in overweight but otherwise healthy adults, Conze and colleagues found that 100, 300 and 1,000 mg of NR a day increased whole-blood NAD+ by 22%, 51% and 142% respectively within two weeks, with no flushing and no difference in adverse events versus placebo.^[1]
• Well tolerated in older adults: Martens and colleagues found six weeks of NR to be well tolerated and to stimulate NAD+ metabolism in healthy middle-aged and older adults, and suggested blood pressure and arterial stiffness as outcomes for future trials.^[2]

NMN in human trials

• Raises NAD+, with the highest levels at higher doses: Yi and colleagues randomised 80 healthy middle-aged adults to placebo or 300, 600 or 900 mg of NMN daily for 60 days. Blood NAD+ rose in all NMN groups and was highest at 600 and 900 mg; six-minute walking distance also increased more than with placebo, and there were no safety issues.^[3]
• Muscle insulin sensitivity: in a 10-week randomised, placebo-controlled trial in postmenopausal women with prediabetes who were overweight or obese, Yoshino and colleagues found that NMN increased muscle insulin sensitivity, while placebo did not.^[4]
• Older men: Igarashi and colleagues found 250 mg a day for 6 or 12 weeks raised blood NAD+ in healthy older men and was well tolerated.^[5]

So which is better?

The trials above each tested one precursor against placebo, in different people, at different doses, measuring different things, so they cannot settle which is better. What they do show is that both raise NAD+-related markers and were well tolerated over weeks to months. A 2026 systematic review by Gallagher and colleagues reached a similar overall view: oral NR and NMN consistently show biochemical target engagement in humans, but effects on functional and healthspan outcomes are heterogeneous and often null, so clinical effectiveness for anti-ageing remains inconclusive.^[6]

Practical points when choosing

• Check the dose against the trials: NMN trials above used 250 to 900 mg a day; NR trials used 100 to 1,000 mg a day.
• Be patient: the trials ran for weeks to months, and most outcomes were lab markers rather than things you would feel.
• Do not stack several NAD products at high doses without talking to your doctor.

Where The Vital Co. fits

The Vital Co. does not sell NR. Vital NMN provides 500 mg of NMN in one capsule a day, within the 250 to 900 mg range used in the NMN trials above, though the product itself was not tested in them. For people who want NMN alongside NAD+ itself, the Longevity Stack combines Vital NMN with Vital NAD+ (500 mg NAD+ with quercetin and resveratrol-standardised Japanese knotweed), and the Longevity & Cellular Stack adds Vital CoQ10 Ubiquinone.

References

1. Conze D, et al. Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults. Scientific Reports. 2019. DOI: 10.1038/s41598-019-46120-z (PMID 31278280)
2. Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications. 2018. DOI: 10.1038/s41467-018-03421-7 (PMID 29599478)
3. Yi L, et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience. 2023. DOI: 10.1007/s11357-022-00705-1 (PMID 36482258)
4. Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021. DOI: 10.1126/science.abe9985 (PMID 33888596)
5. Igarashi M, et al. Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men. npj Aging. 2022. DOI: 10.1038/s41514-022-00084-z (PMID 35927255)
6. Gallagher C, et al. NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Research Reviews. 2026. DOI: 10.1016/j.arr.2026.103057 (PMID 41655607)